MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

MDT

101.45

+0.95%↑

138.61

-0.74%↓

VEEV

225

+2.37%↑

HQY

86.43

+2.1%↑

NEOG

9.92

+0.61%↑

Inicio・Lista de Acciones・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

81.39 2.55

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

78.63

Máximo

82.15

Métricas clave
By Trading Economics
Ingresos	-252M -129M
Ventas	-295M 157M
Margen de beneficio	-82.062
Empleados	1,069
EBITDA	-254M -103M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+22.43% upside

Dividendos
By Dow Jones
Próximas Ganancias	18 feb 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	730M 12B
Apertura anterior	78.84
Cierre anterior	81.39

Noticias sobre sentimiento de mercado

By Acuity

50%

177 / 360 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

29.78 / 33.645 Soporte y Resistencia

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

21 ene 2026, 23:49 UTC

Principales Movimientos del Mercado

Karman Space & Defense Shares Rise as 2026 Forecast Tops Analyst Estimates

21 ene 2026, 21:12 UTC

Principales Movimientos del Mercado

Automaker Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 21:00 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19 Billion

21 ene 2026, 20:29 UTC

Principales Movimientos del Mercado

Chip Makers Gain After Trump Calls Off European Tariffs

21 ene 2026, 20:04 UTC

Principales Movimientos del Mercado

Apparel, Footwear Stocks Rise After Trump Calls Off European Tariffs

21 ene 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Rise as U.S.-Europe Tensions Ease -- Market Talk

21 ene 2026, 23:34 UTC

Charlas de Mercado

Gold Falls Amid Easing U.S.-Europe Tensions Over Greenland -- Market Talk

21 ene 2026, 22:39 UTC

Ganancias

Schwab's Profit Jumps on Surge in Brokerage Activity -- 2nd Update

21 ene 2026, 21:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

21 ene 2026, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 ene 2026, 21:35 UTC

Adquisiciones, fusiones, absorciones

Tesla Stock In Focus as Musk and Ryanair Chief Trade Insults. Should Investors Worry? -- Barrons.com

21 ene 2026, 21:19 UTC

Ganancias

Charles Schwab Earnings Miss Estimates. The Stock Is Rising Anyway. -- Barrons.com

21 ene 2026, 20:45 UTC

Adquisiciones, fusiones, absorciones

Deutsche Borse Group to Acquire Allfunds for $6.19B

21 ene 2026, 20:36 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Hefty Gains -- Market Talk

21 ene 2026, 20:31 UTC

Charlas de Mercado

Oil Settles Higher With Support From Heating Fuel -- Market Talk

21 ene 2026, 20:27 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Expects Combined Company Will Be Able to Achieve Annual Run Rate Pretax Cost Synergies of About EUR60M

21 ene 2026, 20:27 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

21 ene 2026, 20:27 UTC

Charlas de Mercado

Was It a 'TACO' Event? -- Market Talk

21 ene 2026, 20:26 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Has Received Irrevocable Undertakings in Support of Acquisition in Respect of About 48.9% of Allfunds Issued Share Capital Excluding Treasury Shares

21 ene 2026, 20:23 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Allfunds Stockholders to Receive EUR8.80/Shr, Including Cash, Stock and Permitted Dividend

21 ene 2026, 20:21 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse: Agreement Values Allfunds at About EUR5.3B

21 ene 2026, 20:19 UTC

Adquisiciones, fusiones, absorciones

Deutsche Boerse Group Agrees to Buy Allfunds

21 ene 2026, 20:08 UTC

Ganancias

Prologis Revenue Climbs as Warehouse Demand Rebounds -- Update

21 ene 2026, 20:03 UTC

Charlas de Mercado

Precious Metals Drop After Trump Posts About Greenland Deal -- Market Talk

21 ene 2026, 19:51 UTC

Charlas de Mercado

Treasury Markets React to Trump's Softer Tone About Greenland -- Market Talk

21 ene 2026, 19:43 UTC

Charlas de Mercado

U.S. Ethanol Production Expected to Slip -- Market Talk

21 ene 2026, 19:31 UTC

Charlas de Mercado

Gold Settles at Fresh All-Time High -- Market Talk

21 ene 2026, 19:24 UTC

Ganancias

Johnson & Johnson Tops Earnings Estimates and Issues a Solid Outlook. The Stock Falls. -- Barrons.com

21 ene 2026, 19:10 UTC

Charlas de Mercado

Mexican Inflation Seen Picking Up in Early January -- Market Talk

21 ene 2026, 18:57 UTC

Charlas de Mercado

DAVOS: IBM CEO Krishna Says World Is More Volatile Now -- Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

22.43% repunte

Estimación a 12 meses

Media 94.92 USD 22.43%

Máximo 110 USD

Mínimo 77 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

Comprar

Mantener

Vender

De acuerdo con 14 analistas que ofrecen calificaciones bursátiles a para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Sentimiento

By Acuity

177 / 360 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.